title: [Developments in pyoderma gangrenosum therapy in 2015].
abstract: Diagnosis of pyoderma gangrenosum in 2014 continues to be made on clinical grounds, with the main form comprising an ulcer having poorly delineated purplish edges. The diagnostic criteria have been recently modified so as to rule out differential diagnoses (10% of retrospective series of pyoderma patients). The condition is commonly associated with other diseases (75%) such as emerging endocrine diseases (36.7%), and classical gastrointestinal, rheumatological and haematological diseases. The new concepts of PAPA and PASH syndromes, belonging to the category of auto-inflammatory diseases, provide new therapeutic perspectives. Corticosteroids continue to be the first-line therapy, along with immunosuppressant drugs in the event of steroid dependence. Second-line treatments consisting biotherapies show promise and interleukin-1 inhibitors have exhibited potential against pyoderma syndrome.
authors.affiliation: Service de dermatologie, université catholique de Lille, hôpital Saint-Vincent-de-Paul, boulevard de Belfort, BP 387, 59020 Lille, France. Electronic address: Modiano.philippe@ghicl.net.
authors.forename: P
authors.initials: P
authors.lastname: Modiano
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000150:complications; D058752:Free Tissue Flaps; D005767:Gastrointestinal Diseases / Q000150:complications; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D012216:Rheumatic Diseases / Q000150:complications
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007166:Immunosuppressive Agents
keywords: Auto-inflammatory diseases; Maladies auto-inflammatoires; PASH; Pyoderma gangrenosum